Teachers Retirement System of The State of Kentucky boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 85.8% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 43,450 shares of the biotechnology company’s stock after purchasing an additional 20,062 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in United Therapeutics were worth $7,795,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in UTHR. MCF Advisors LLC bought a new stake in shares of United Therapeutics in the 1st quarter valued at $34,000. NuWave Investment Management LLC bought a new stake in United Therapeutics in the first quarter valued at $53,000. Rockefeller Capital Management L.P. raised its holdings in shares of United Therapeutics by 243.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 254 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 180 shares during the period. Laurel Wealth Planning LLC bought a new position in shares of United Therapeutics during the 1st quarter worth about $54,000. Finally, Sandy Cove Advisors LLC bought a new stake in United Therapeutics in the 1st quarter valued at about $58,000. 95.57% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at United Therapeutics
In related news, Director Christopher Causey sold 3,500 shares of the business’s stock in a transaction dated Tuesday, August 23rd. The stock was sold at an average price of $224.96, for a total value of $787,360.00. Following the sale, the director now directly owns 2,835 shares in the company, valued at approximately $637,761.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Raymond Dwek sold 2,160 shares of the firm’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $241.29, for a total value of $521,186.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher Causey sold 3,500 shares of the business’s stock in a transaction on Tuesday, August 23rd. The shares were sold at an average price of $224.96, for a total value of $787,360.00. Following the sale, the director now owns 2,835 shares in the company, valued at $637,761.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,212 shares of company stock worth $6,330,244. 12.40% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
United Therapeutics Stock Down 1.1 %
UTHR opened at $218.11 on Friday. United Therapeutics Co. has a twelve month low of $158.38 and a twelve month high of $245.48. The company’s 50-day moving average price is $224.94 and its two-hundred day moving average price is $208.59. The stock has a market cap of $9.93 billion, a price-to-earnings ratio of 16.51, a PEG ratio of 4.24 and a beta of 0.54. The company has a quick ratio of 7.83, a current ratio of 8.10 and a debt-to-equity ratio of 0.19.
United Therapeutics (NASDAQ:UTHR – Get Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported $2.41 earnings per share for the quarter, missing the consensus estimate of $4.10 by ($1.69). United Therapeutics had a net margin of 35.27% and a return on equity of 15.50%. The firm had revenue of $466.90 million for the quarter, compared to the consensus estimate of $461.06 million. During the same period last year, the company posted $3.65 earnings per share. United Therapeutics’s revenue for the quarter was up 4.6% on a year-over-year basis. As a group, equities analysts expect that United Therapeutics Co. will post 15.21 earnings per share for the current year.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.